Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
about
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@en
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@nl
type
label
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@en
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@nl
prefLabel
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@en
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@nl
P2093
P2860
P50
P356
P1433
P1476
Simultaneous targeting of EGFR ...... ous cell carcinoma cell lines.
@en
P2093
Erik Fransen
Hasan Baysal
Ines De Pauw
Jan Baptist Vermorken
Jolien Van den Bossche
Patrick Pauwels
Vanessa Deschoolmeester
P2860
P304
P356
10.1002/1878-0261.12197
P577
2018-05-01T00:00:00Z